Drug intelligence / Profile preview

PRS NEUROPAIN

Development stage: Unknown
Lead developer: Peaches Biotech
Modality: Cell Therapies

Overview

PRS NEUROPAIN (also known as PRS Microglia) is a microglial-based cell therapy developed by Peaches Biotech for the treatment of neuropathic pain, specifically trigeminal neuralgia. Developed using the company's proprietary PRS (Selective Rich Plasma) platform, the therapy utilizes cellular immunomodulation to restore normal microglial function and modulate neuroinflammation. The mechanism of action involves preventing the antigenic recognition of Stress-Associated Patterns (SAPs) and Damage-Associated Molecular Patterns (DAMPs) by neuronal microglia. The drug is currently being evaluated in the Phase 1 NEUROPAINBOOST clinical trial at the University Hospital of Fuenlabrada in Madrid, Spain.

Brand names: PRS NEUROPAIN
Other names: NEUROPAINPRS Microglial

Beyond the preview

Go deeper on PRS NEUROPAIN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRS NEUROPAIN.

Explore the full profile